Grace Therapeutics, Inc. Operating Income Loss

• Grace Therapeutics, Inc. showed a decrease of -29.8% in Operating Income Loss from 2024 to 2025.
• This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Grace Therapeutics, Inc.'s Operating Income Loss has grown by 51.5%.
• Historical annual values: Fiscal year 2025: -$16.68 million | Fiscal year 2024: -$12.85 million | Fiscal year 2023: -$52.16 million | Fiscal year 2022: -$15.59 million | Fiscal year 2021: -$16.42 million | Fiscal year 2020: -$24.44 million | Fiscal year 2019: -$34.41 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026